The Mucolipidosis Collaborative Network (MCRN) and Cure Mucolipidosis (Cure ML) announced that they will be able to initiate the Natural History studies on a model of mucolipidosis type II (ML II) in 2022. M6PT met with both the MCRN and Cure ML to provide an update on the status of M6PT’s preclinical development programs for ML II/ML III, and to discuss collaboration efforts to develop and foster the discovery and development of new therapies for ML.

Read More

Contact us to learn more:

M6P Therapeutics:

Alex Van Rees, SmithSolve
973-442-1555 x111

Recommended Posts